Apyx Medical Receives Buy Rating from Craig-Hallum Analyst

Craig-Hallum analyst Matt Hewitt maintains a Buy rating on Apyx Medical (APYX), with an average return of -6.7% and a 38.80% success rate. The company's shares closed at $0.89 last Friday. The analyst consensus rating for Apyx Medical is Moderate Buy.

Apyx Medical Corporation (Nasdaq: APYX), an advanced energy technology company, recently announced the publication of two peer-reviewed clinical studies evaluating the use of its proprietary Renuvion® device during body contouring procedures that also included lipoabdominoplasty. The studies, published in Aesthetic Plastic Surgery and Aesthetic Surgery Journal Open Forum, reported favorable clinical outcomes and safety data for Renuvion® when used in these procedures.

The first study, authored by Mauro Barone, MD et al., is the first prospective, randomized controlled trial to evaluate Renuvion® in procedures that also included lipoabdominoplasty for patients with abdominal skin laxity following significant weight loss. The study found that patients in the Renuvion® group demonstrated improvements in abdominal skin laxity and excess skin, along with higher satisfaction scores at 6 months, 1 year, and 2 years post-procedure. The study concluded that Renuvion® provided a significantly greater improvement compared to lipoabdominoplasty alone, without an increased rate of complications [1].

The second study, authored by Paul Vanek, MD, presented findings from a retrospective study of 77 patients treated with ultrasound-assisted lipoabdominoplasty (UAL), with or without Renuvion®. The study found no statistically significant difference between groups in the occurrence of significant adverse events, indicating that the addition of Renuvion® did not increase the incidence of complications, despite the Renuvion® group undergoing more concurrent procedures and longer surgical times [2].

Charlie Goodwin, President and Chief Executive Officer of Apyx Medical, stated, "We estimate over 15 million patients are currently using GLP-1 drugs, many of which, we believe, will seek treatment for loose and lax skin due to the associated rapid weight loss. Renuvion® is the only FDA-cleared device for addressing loose and lax skin post-liposuction in aesthetic body contouring procedures, and we are uniquely positioned to treat this growing patient population." Goodwin emphasized that these newly published studies further solidify the safety and value of Renuvion® in aesthetic body contouring [1].

While the clinical studies provide positive evidence for Renuvion®, Apyx Medical's stock has faced significant challenges. The company's shares have declined by 29% in the past year, with a 25% drop in the last month alone. The company's price-to-sales (P/S) ratio is currently 0.7x, which is lower than the industry average. Analysts have noted that the low P/S ratio may be justified due to the company's disappointing revenue performance and the expectation of anemic growth in the coming years [2].

Despite the stock's decline, Craig-Hallum analyst Matt Hewitt maintains a Buy rating on Apyx Medical, with an average return of -6.7% and a 38.80% success rate. The analyst consensus rating for Apyx Medical is Moderate Buy [3].

References

[1] https://www.globenewswire.com/news-release/2025/04/29/3070104/0/en/Apyx-Medical-Corporation-Announces-Two-Peer-Reviewed-Publications-on-the-Use-of-Renuvion-in-Abdominal-Body-Contouring-Procedures.html
[2] https://simplywall.st/stocks/us/healthcare/nasdaq-apyx/apyx-medical/news/the-market-doesnt-like-what-it-sees-from-apyx-medical-corpor
[3] https://www.craighallum.com/analysts/matthew-hewitt/apyx-medical-corporation-nasdaq-apyx